Japan to start OTC sales of emergency contraceptive in February

Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.

Daiichi Sankyo announced on December 18 that it will launch over-the-counter sales of the emergency contraceptive pill Norlevo starting February 2 next year. Produced by Aska Pharmaceutical, the drug received approval from the health ministry in October for OTC availability, making it the first of its kind in Japan without requiring a prescription.

There are no age restrictions on purchasing Norlevo, allowing anyone to buy it. However, for safety, it must be taken under the supervision of a trained pharmacist. The pill is effective in preventing pregnancy in about 80% of cases when taken within 72 hours of intercourse. Its suggested retail price is ¥7,480 per pill.

This move aims to improve access to contraception, offering a new option for women's health management in the country. Key terms include pharmaceuticals, health, pregnancy, and birth control.

Liittyvät artikkelit

Illustration depicting a woman self-screening for medication abortion eligibility using prototype OTC packaging from a JAMA study.
AI:n luoma kuva

Study finds many patients can self-screen for medication abortion eligibility using prototype labeling

Raportoinut AI AI:n luoma kuva Faktatarkistettu

A study published April 6, 2026, in JAMA Internal Medicine found that people seeking medication abortion often reached the same eligibility conclusions as clinicians when using prototype “over-the-counter-style” packaging and a drug facts label. Researchers and outside experts said the results add to evidence that self-screening could work, though any move to over-the-counter sales would face major regulatory and political hurdles.

The Diet passed legislation requiring higher co-payments for about 1,100 prescription drugs that resemble over-the-counter products, with the changes set to begin in March 2027.

Raportoinut AI

The U.S. Supreme Court on Thursday issued an emergency order permitting the mail distribution of the abortion drug mifepristone to continue nationwide. The unsigned ruling temporarily blocked a federal appeals court decision that had struck down a Biden-era policy allowing online prescriptions and shipments.

A unanimous three-judge panel of the U.S. Court of Appeals for the Fifth Circuit on Friday issued a temporary nationwide order that freezes federal rules allowing mifepristone to be prescribed via telemedicine and sent by mail, siding with Louisiana in a lawsuit challenging the FDA’s 2023 changes.

Raportoinut AI

Chile's Public Health Institute (ISP) issued a pharmaceutical alert ordering the voluntary recall of Laboratorio Chile S.A.'s loratadine syrup 5 mg/5 ml after detecting out-of-specification impurities in stability studies. The action targets batches EWOA, EWOB, and EWOC, expiring in September 2026.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää